Screener
Viridian Therapeutics, Inc. VRDN EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s EBITDA margin?
- Viridian Therapeutics, Inc. (VRDN) reported EBITDA margin of -569% in Q2 2026.
- How has Viridian Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Viridian Therapeutics, Inc.'s EBITDA margin increased by 99.5% year-over-year, from -121,672.8% to -569%.
- What is the long-term trend for Viridian Therapeutics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s EBITDA margin has grown at a -45.3% compound annual growth rate (CAGR), from -10,489.6% to -512.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Viridian Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude